| Revenue growth | 36% YoY Q4 growth; full year FY26 remained largely flat. |
|---|---|
| Margins | 34.3% EBITDA margin in Q4; long-term sustainable range 26-28%. |
| Demand visibility | Low in Europe due to war; improving pilot-to-commercial transitions. |
| Management confidence | Balanced; emphasized deliberate groundwork over aggressive top-line expansion. |
Growth
Q4 revenue grew 36% YoY and 56% QoQ; EBITDA surged 69% sequentially due to better product mix.
Outlook
Block 7 commercial production starts Q2 FY27; CRAMS expected to drive visible outcomes throughout FY27.
Risks
Global geopolitical volatility and prolonged regulatory approvals in Europe/Japan delay commercialization of high-margin CRAMS projects.
Earnings Call filed with BSE, NSE: SGRL. Summary written with AI assistance from the document.
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹717.35
- Market cap
- ₹920.9 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 59.7×Sector 47.4×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shree Ganesh Remedies Ltd
All →Shree Ganesh Remedies Annual General Meeting
Shree Ganesh Remedies held its 31st Annual General Meeting on September 12, 2026. The meeting transacted ordinary and special business items, including director and auditor appointments.
Shree Ganesh Remedies Annual General Meeting
Shree Ganesh Remedies Limited has issued the notice for its 31st Annual General Meeting scheduled for September 12, 2026. Shareholders will consider key resolutions and director appointments.
Shree Ganesh Remedies Annual Report
Shree Ganesh Remedies Limited has filed its Annual Report for FY 2025-26. It also includes the notice for the 31st Annual General Meeting on September 12, 2026.
Shree Ganesh Remedies Investor Presentation: Key Takeaways
Q1FY27 was challenging with Revenue/PAT declining 42%/68% YoY due to subdued European demand and termination of a distributor agreement. Management shifted focus to direct customer engagement and CRAMS projects.
Shree Ganesh Remedies Results Update
Shree Ganesh Remedies announced its Q1FY27 financial results. Revenue from operations stood at ₹14.36 Crore, with a PAT of ₹1.12 Crore.
- Value
- ₹14.36 Cr
Shree Ganesh Remedies Other Announcement
Shree Ganesh Remedies Limited has appointed M/s. M. I. Prajapati & Associates LLP as the company's Cost Auditor for a term of 12 months.
- Execution
- 12 months